| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015557797 |
| P356 | DOI | 10.1007/S00125-010-1922-6 |
| P953 | full work available at URL | https://link.springer.com/content/pdf/10.1007%2Fs00125-010-1922-6.pdf |
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20882268/pdf/?tool=EBI | ||
| https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20882268/?tool=EBI | ||
| https://europepmc.org/articles/PMC2995871 | ||
| https://europepmc.org/articles/PMC2995871?pdf=render | ||
| http://link.springer.com/content/pdf/10.1007/s00125-010-1922-6 | ||
| P932 | PMC publication ID | 2995871 |
| P698 | PubMed publication ID | 20882268 |
| P5875 | ResearchGate publication ID | 46821391 |
| P50 | author | Dick de Zeeuw | Q86373033 |
| P2093 | author name string | B. M. Brenner | |
| H-H Parving | |||
| Y. Miao | |||
| M. E. Cooper | |||
| S. Shahinfar | |||
| D. Dobre | |||
| D. Grobbee | |||
| H. J Lambers Heerspink | |||
| P2860 | cites work | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system | Q35856246 | ||
| The frequency of hyperkalemia and its significance in chronic kidney disease. | Q36530203 | ||
| Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors | Q37691122 | ||
| Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease | Q43244823 | ||
| Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy | Q43270031 | ||
| The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study | Q44358769 | ||
| Is suboptimal phlebotomy technique impacting on potassium results for primary care? | Q44480968 | ||
| Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit | Q46318699 | ||
| Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). | Q46340479 | ||
| Spurious hyperkalaemia due to EDTA contamination: common and not always easy to identify | Q46392367 | ||
| Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? | Q46529781 | ||
| Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program | Q46904673 | ||
| Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe. | Q50605243 | ||
| Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. | Q54152709 | ||
| ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. | Q54273650 | ||
| The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) | Q57703684 | ||
| Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in man | Q67546087 | ||
| Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression | Q70758605 | ||
| Trans-tubular potassium gradient in patients with drug-induced hyperkalemia | Q74441029 | ||
| No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients | Q79665661 | ||
| Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism | Q80019741 | ||
| Analysis of factors causing hyperkalemia | Q80492192 | ||
| Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis | Q82295148 | ||
| P2507 | corrigendum / erratum | Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial | Q93562814 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | losartan | Q410074 |
| P304 | page(s) | 44-50 | |
| P577 | publication date | 2010-09-30 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial | |
| P478 | volume | 54 |
| Q64100077 | A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology |
| Q85964436 | A novel approach for establishing cardiovascular drug efficacy |
| Q44455773 | A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers |
| Q41154605 | Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study |
| Q30829341 | Can you trust your animal study data? |
| Q86554880 | Clinical trials: New nonabsorbable potassium-exchange resins in hyperkalaemia |
| Q60922804 | Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care |
| Q83092091 | Diabetes: Treatment with losartan increases risk of adverse renal outcomes |
| Q38232308 | Drug-induced hyperkalemia |
| Q86489714 | Dual RAAS blockade has dual effects on outcome |
| Q37240299 | Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial |
| Q36127484 | Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis |
| Q85940309 | Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study |
| Q93539017 | High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter] |
| Q84395901 | High serum potassium levels after using losartan can reflect more severe renal disease |
| Q34812460 | Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease |
| Q38068099 | Improving the efficacy of RAAS blockade in patients with chronic kidney disease |
| Q38052452 | Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy |
| Q38249892 | Management of hyperkalaemia in chronic kidney disease |
| Q37853831 | Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. |
| Q35626544 | Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney disease |
| Q90626583 | Mitigating risk of aldosterone in diabetic kidney disease |
| Q91672613 | Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice? |
| Q37219043 | Novel drugs and intervention strategies for the treatment of chronic kidney disease |
| Q50095858 | Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. |
| Q38544101 | Potential New Agents for the Management of Hyperkalemia |
| Q48098900 | Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy |
| Q51100638 | Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. |
| Q47669329 | Revisiting RAAS blockade in CKD with newer potassium-binding drugs |
| Q52648659 | Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. |
| Q57214519 | Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response |
| Q36557863 | The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarction |
| Q38168046 | The effect of RAAS blockade on the progression of diabetic nephropathy |
| Q83334449 | The effect of losartan and carvedilol on renal haemodynamics and altered metabolism in fructose-fed Sprague-Dawley rats |
| Q44532842 | The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial |
| Q35760302 | The kidney in type 2 diabetes therapy |
| Q36125465 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers |
| Q53586663 | [Effect of Astragali and Angelica particle on proteinuria in Chinese patients with primary glomerulonephritis]. |
Search more.